Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.48 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4508293 | 0.87 | GRM5 (0.53) | HRH3KCNH2HTR1AGRIK1GRIA1 | |
| SCHEMBL4505935 | 0.87 | KCNH2 (0.60) | HRH3KCNH2HTR1ASLC6A4HRH1 | |
| SCHEMBL4506046 | 0.77 | RORC (0.45) | GRIK1GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL4502458 | 0.77 | KCNH2 (0.56) | HRH3KCNH2HTR1ASLC6A4HRH1 | |
| SCHEMBL4505214 | 0.76 | GRIK1 (0.43) | HRH3KCNH2HTR1AGRIK1GRIA1 | |
| SCHEMBL4502955 | 0.75 | MAPK14 (0.58) | HRH3KCNH2 | |
| SCHEMBL8467965 | 0.74 | AOC3 (0.59) | ITGB3ITGA2B | |
| SCHEMBL7797432 | 0.74 | ITGB3 (0.63) | ITGB3ITGA2B | |
| SCHEMBL4501822 | 0.74 | MAP3K5 (0.49) | HTR1AGRIK1GRIA1GRIA2GRIA3 | |
| SCHEMBL23387571 | 0.73 | POLB (0.55) | POLBITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | HRH3 3910/4885KCNH2 3795/4885HTR1A 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.